Autor/autores: José Ángel Alcalá Partera
, Juan Luis Prados Ojeda
Fecha Publicación: 26/07/2017
Área temática: Tratamientos .
Reina Sofia University Hospital. Dept. of Mental Health. Córdoba. Spain.
13th Wold Congress of Biological Psychiatry. 18-22 June 2017. Copenhagen. Denmark.
The appearance of paliperidone palmitate for quarterly use is an extraordinary advance and novelty from a pharmacokinetic point of view. This treatment may be initiated in patients who are adequately treated with the monthly use formulation for at least 4 months and not require dose adjustment at this time interval.
The objectives of this study are to quantify short- and long-term changes in the symptoms control and patient safety profile.
Palabras clave: PALIPERIDONE, PALMITATE, 3-MONTH FORMULATION,